CARLSBAD, Calif. — When patients with vitiligo see Jessica Shiu, MD, PhD, for the first time, some mention that prior healthcare providers have told them that vitiligo is merely a cosmetic issue — ...

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis. Atopic dermatitis (AD) and ...

The Global Vitiligo Treatment Market is expanding due to rising prevalence and innovative JAK inhibitors improving efficacy, yet faces challenges from high costs and limited insurance coverage.

LEATHERHEAD, England--(BUSINESS WIRE)-- Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® ...

For patients who had 12 months of continuous health care coverage before and after receiving a diagnosis of vitiligo, treatment rates were at suboptimal levels. Using data from the Merative MarketScan ...

It was found that adding NB-UVB light therapy to ruxolitinib (Opzelura) 1.5% cream helped many vitiligo patients who did not respond early to treatment achieve faster and more noticeable skin ...

Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease ...

Please provide your email address to receive an email when new articles are posted on . Melanocyte keratinocyte transplantation can yield significant repigmentation ranging from 70% to 100%. The ...

The company advanced its main asset, EB06, which is being developed for the treatment of vitiligo, with key preparations underway for a manufacturing campaign. Edesa anticipates submitting data to the ...

Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo [1,2] ...

International vitiligo experts have published new recommendations in two parts — one dedicated to management algorithms, the other to specific treatment recommendations — to update the text from 2013.